Responses
Regular and Young Investigator Award Abstracts
Combination Immunotherapies
794 TKM-011, Anti-CD20 antibody confers multi-properties against burkitt’s lymphoma in comparable efficacy to rituximab and obinutuzumab
Compose a Response to This Article
Other responses
No responses have been published for this article.